Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer
H Sito, SC Tan - Molecular Biology Reports, 2024 - Springer
Platinum-based chemotherapy (PBC) is a widely used treatment for various solid tumors,
including non-small cell lung cancer (NSCLC). However, its efficacy is often compromised …
including non-small cell lung cancer (NSCLC). However, its efficacy is often compromised …
[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic …
W Guo, T Zhang, B Wang, L Mao… - BioMed Research …, 2022 - Wiley Online Library
Objective. To systematically evaluate the efficacy and safety of pembrolizumab (PD‐1/PD‐L
inhibitor) and adjuvant chemotherapy to treat NSCLC and provide evidence‐based …
inhibitor) and adjuvant chemotherapy to treat NSCLC and provide evidence‐based …
[HTML][HTML] High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts
AB Schulze, DV Wenge, G Evers… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related
mortality worldwide and its most important risk factor is tobacco smoking. While smoking is …
mortality worldwide and its most important risk factor is tobacco smoking. While smoking is …
A novel DNA damage repair gene-related prognostic model for evaluating the prognosis and tumor microenvironment infiltration of esophageal squamous cell …
D Guo, X Zhang, X Du, W Yao, W Shen, S Zhu - BMC Medical Genomics, 2023 - Springer
Background This study aimed to investigate the potential prognostic value of DNA damage
repair genes (DDRGs) in esophageal squamous cell carcinoma (ESCC) and their …
repair genes (DDRGs) in esophageal squamous cell carcinoma (ESCC) and their …